Published in Cancer Res on September 01, 2005
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
Elevated mitochondrial superoxide disrupts normal T cell development, impairing adaptive immune responses to an influenza challenge. Free Radic Biol Med (2010) 1.13
IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood (2009) 1.07
Targeting the oncogene B lymphoma deregulator IgH 3' regulatory region does not impede the in vivo inflammatory response in mice. Oncoscience (2014) 0.91
The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. Leukemia (2014) 0.91
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics (2007) 0.86
Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood (2011) 0.84
The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia (2012) 0.84
CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. Mol Cancer (2006) 0.84
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res (2014) 0.78
Efficient role of IgH 3' regulatory region deficient B-cells in the development of oil granulomas. Oncotarget (2016) 0.76
The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis. Oncotarget (2016) 0.75
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood (2004) 5.10
Pillars Article: Cell Type-Specific Chromatin Structure Determines the Targeting of V(D)J Recombinase Activity In Vitro. Cell. 1996. 85: 887-897. J Immunol (2015) 4.98
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res (2005) 4.84
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res (2009) 3.87
Aggressive lymphomas. N Engl J Med (2010) 3.86
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 3.59
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev (2006) 3.49
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 3.41
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol (2004) 2.90
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 2.79
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature (2006) 2.60
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood (2010) 2.49
Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell (2007) 2.46
Pathogenesis of human B cell lymphomas. Annu Rev Immunol (2012) 2.44
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol (2002) 2.37
Regulation of AID expression in the immune response. J Exp Med (2007) 2.35
Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol (2004) 2.35
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med (2013) 2.31
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol (2003) 2.30
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol (2010) 2.30
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood (2005) 2.19
AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med (2008) 2.10
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood (2006) 2.10
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol (2006) 2.02
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood (2008) 2.00
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res (2008) 1.95
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med (2007) 1.94
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature (2008) 1.91
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (2013) 1.91
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.90
Malignant pirates of the immune system. Nat Immunol (2011) 1.87
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest (2009) 1.83
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res (2005) 1.83
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol (2007) 1.80
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica (2009) 1.79
Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood (2010) 1.76
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood (2014) 1.71
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med (2012) 1.69
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood (2003) 1.69
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood (2012) 1.68
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res (2011) 1.67
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood (2014) 1.66
IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res (2009) 1.61
Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol (2003) 1.61
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood (2007) 1.60
Characterization of early stages of human B cell development by gene expression profiling. J Immunol (2007) 1.60
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood (2003) 1.58
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol (2004) 1.57
IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A (2002) 1.55
Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest (2004) 1.53